Magnetic Resonance Imaging Clinical Trial
Official title:
Drug Use Investigation of Gadovist
NCT number | NCT02540967 |
Other study ID # | 17512 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 27, 2015 |
Est. completion date | November 2, 2017 |
Verified date | November 2023 |
Source | Bayer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objectives of this study are to investigate the safety and effectiveness of Gadovist.
Status | Completed |
Enrollment | 3357 |
Est. completion date | November 2, 2017 |
Est. primary completion date | November 2, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Patients who perform contrast enhanced Magnetic Resonance Imaging (MRI) with Gadovist. Exclusion Criteria: - Patients who are contraindicated based on approved label. |
Country | Name | City | State |
---|---|---|---|
Japan | Many Locations | Multiple Locations |
Lead Sponsor | Collaborator |
---|---|
Bayer |
Japan,
Tsushima Y, Awai K, Shinoda G, Miyoshi H, Chosa M, Sunaya T, Endrikat J. Post-marketing surveillance of gadobutrol for contrast-enhanced magnetic resonance imaging in Japan. Jpn J Radiol. 2018 Nov;36(11):676-685. doi: 10.1007/s11604-018-0778-4. Epub 2018 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of episodes of adverse events as a measure of safety and tolerability | Up to 3 days | ||
Secondary | Number of episodes of adverse drug reactions and adverse events | In subpopulations | Up to 3 days | |
Secondary | Contrast enhancement | Investigator Discretion as very improved , improved, not changed, degraded, not evaluable.
MRI- Magnetic Resonance Imaging |
At the time of MRI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03785171 -
Predicative Value of Multimodal MRI in Moyamoya Disease
|
||
Not yet recruiting |
NCT03726788 -
Intra Articular Injection of Botulinum Toxin Versus Corticoids in Gonarthrosis
|
Phase 2 | |
Active, not recruiting |
NCT01956409 -
Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis
|
Phase 4 | |
Completed |
NCT01660841 -
Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging
|
Phase 3 | |
Recruiting |
NCT03635619 -
The Application of 3T MRI in Esophageal Cancer
|
||
Recruiting |
NCT03658343 -
T2* MRI Analysis for Sarcoma
|
N/A | |
Recruiting |
NCT04555642 -
Early Diagnosis of Therapy-associated Cardiotoxicity Basing on Multi-tracer Multimodality PET/MRI
|
||
Active, not recruiting |
NCT03441867 -
Neuroimaging Biomarker for Seizures
|
N/A | |
Recruiting |
NCT04850001 -
Cognitive Decline in Asymptomatic Intracranial Stenosis Patients: A 1-Year Follow-Up Study
|
||
Not yet recruiting |
NCT05816213 -
Point-of-care Low-field MRI in Acute Stroke
|
||
Active, not recruiting |
NCT05498623 -
MR Fingerprinting for Diagnostic of Prostate Cancer
|
||
Recruiting |
NCT04257747 -
Qualitative and Quantitative Evaluation of Vascular Flows of Radial, Ulnar and Interdigital Arterial Trees Under Normal and Pathological Conditions by 3 Tesla MRI
|
N/A | |
Recruiting |
NCT04996615 -
Artificial Intelligence Analysis for Magnetic Resonance Imaging in Screening Breast Cancer in High-risk Women
|
||
Recruiting |
NCT05889117 -
Brain Stimulation for Concussion
|
N/A | |
Completed |
NCT05103189 -
4D-flow Cardiac MRI to Assess Pulmonary Arterial Pressure in Pulmonary Hypertension
|
N/A | |
Completed |
NCT02567318 -
Is the Volume of the Caudate Nuclei Associated With Area of Secondary Hyperalgesia?
|
N/A | |
Recruiting |
NCT02834585 -
Magnetic Resonance Imaging or Ultrasound in Soft Tissue Tumors (MUSTT)
|
N/A | |
Active, not recruiting |
NCT02446665 -
Disease Status in Primary Sclerosing Cholangitis by Elastography
|
N/A | |
Completed |
NCT01721785 -
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer
|
N/A | |
Completed |
NCT01223404 -
Nicotinic Modulation of the Default Network
|
N/A |